Fatty liver disease is famously quiet. Most people who have it feel perfectly fine, and the condition is often discovered accidentally during imaging or blood work ordered for something else entirely. There is no single test that definitively confirms fatty liver on its own; instead, doctors piece together clues from your symptoms (or lack of them), blood results, and imaging studies. The path from suspicion to diagnosis usually starts with something subtle, sometimes as unremarkable as a mildly elevated liver enzyme on a routine panel.
Why Fatty Liver Rarely Announces Itself
The liver has an enormous functional reserve. It can accumulate a significant amount of fat before it starts sending distress signals you can feel. Most people with early-stage fatty liver have no symptoms at all. When symptoms do eventually appear, they tend to be vague: fatigue, a dull ache or sense of fullness in the upper right abdomen, and sometimes general malaise. Of these, fatigue is by far the most common complaint across chronic liver diseases, reported by roughly half to more than four-fifths of patients.1PubMed Central. Importance of fatigue and its measurement in chronic liver disease The frustrating part is that the severity of the fatigue does not reliably track with how advanced the liver disease actually is. You can feel exhausted with mild fat accumulation or feel little fatigue with more serious inflammation.
This disconnect between how you feel and what is happening inside the liver is exactly why fatty liver is underdiagnosed. If you are waiting for your body to sound an alarm, the disease can progress silently through simple fat buildup to inflammation (steatohepatitis) and eventually scarring (fibrosis). The goal of modern screening is to catch things well before that progression.
Physical Clues Worth Paying Attention To
A standard physical exam is not going to diagnose fatty liver, but certain findings should raise a flag. The most underappreciated one is acanthosis nigricans, those dark, velvety patches of skin that often appear on the neck, armpits, or knuckles. These patches signal insulin resistance, and insulin resistance is one of the strongest drivers of fat accumulation in the liver. One study found that acanthosis nigricans on the knuckles roughly doubled the odds of having liver steatosis, and the presence of these skin changes predicted higher grades of fat buildup.2PubMed Central. Acanthosis Nigricans as a Clinical Risk Marker for Metabolic Dysfunction-Associated Steatotic Liver Disease In people with type 2 diabetes specifically, acanthosis nigricans has been flagged as a potential early clinical marker for both liver fat and liver fibrosis.3PubMed. Acanthosis nigricans independently predicts hepatic fibrosis in people with type 2 diabetes in North India
Among diabetic patients, skin findings in general are extremely common. In one study of over 300 participants with diabetes, about 69% had some kind of skin manifestation, and acanthosis nigricans was the single most frequent finding.4PubMed Central. Evaluation of Cutaneous Manifestations in Patients With Diabetes Mellitus: Association With Non-alcoholic Fatty Liver Disease and Other Gastrointestinal Complications None of this means dark skin patches prove you have fatty liver. But if you notice them and also carry other metabolic risk factors like excess weight around your midsection or elevated blood sugar, it is worth mentioning to your doctor.
Beyond skin changes, your doctor may feel for an enlarged liver during a physical exam, or note central obesity and elevated blood pressure. These are clues that prompt further testing, not diagnoses in themselves.
What Blood Tests Reveal and What They Miss
Routine blood work is usually the first objective clue. Liver enzymes, particularly ALT (alanine aminotransferase) and GGT (gamma-glutamyl transferase), are the most commonly checked markers. When ALT rises above about 40 U/L and GGT above about 30 U/L, the positive predictive value for fatty liver goes up meaningfully.5PubMed Central. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes On the flip side, very low ALT and GGT levels are reasonably good at ruling fatty liver out.
Here is the catch that trips people up: normal liver enzymes do not guarantee a healthy liver. A substantial number of people with biopsy-confirmed fatty liver have ALT levels that sit comfortably within the standard “normal” reference range. This is especially true in women and in children. One study of obese children found that using the conventional ALT cutoff of 40 IU/L caught only about 61% of boys and 36% of girls with fatty liver disease. Lowering the threshold improved detection dramatically, catching about 84% of boys and 74% of girls.6Journal of the Formosan Medical Association. Updated upper limits of normal serum alanine aminotrasferase levels for screening metabolic dysfunction-associated fatty liver disease in obese children The takeaway is that a “normal” ALT on your lab report does not necessarily mean your liver is free of fat.
Beyond individual enzyme levels, doctors sometimes use composite scores that combine blood test results with basic clinical information. The most widely used is the FIB-4 index, which plugs in your age, platelet count, ALT, and AST to estimate the likelihood of significant liver scarring. At a cutoff of 1.3, the FIB-4 has a negative predictive value around 84%, meaning a low score is fairly reassuring that advanced fibrosis is not present.7PubMed Central. Diagnostic accuracy of the Fibrosis-4 (FIB-4) index for advanced liver fibrosis in Qatari patients with MASLD: Comparison with liver biopsy and FibroScan But its sensitivity and specificity hover in the mid-to-upper 60% range, so a worrying score needs follow-up with imaging rather than being taken as a final answer. Simple blood-based scores like FIB-4 are less accurate than more complex tests or imaging-based measurements of liver stiffness, though they remain valuable as an initial screening step because they cost almost nothing and require no special equipment.8PubMed Central. Advances in non-invasive assessment of hepatic fibrosis
Ultrasound as the First-Line Imaging Test
If your blood work or risk profile raises suspicion, the next step is usually an abdominal ultrasound. It is cheap, widely available, painless, and involves no radiation. The radiologist looks for a characteristic bright, echogenic appearance of the liver compared to the kidney. A meta-analysis pooling data from over 2,800 patients found that ultrasound detects moderate-to-severe fatty liver with about 85% sensitivity and 94% specificity.9PubMed Central. Diagnostic Accuracy and Reliability of Ultrasonography for the Detection of Fatty Liver: A Meta-Analysis Those numbers look impressive, but they come with an important caveat: ultrasound is much less reliable when less than about a third of the liver is affected by fat.10PubMed Central. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease If you have mild or early fatty liver, an ultrasound can miss it entirely.
Ultrasound also cannot tell you how much scarring is present in the liver. It sees fat reasonably well but is essentially blind to fibrosis. So a clean ultrasound does not rule out meaningful liver disease, and an ultrasound showing fatty liver does not tell you whether the condition has progressed beyond simple fat accumulation. For those questions, you need different tools.
FibroScan and What the Numbers Mean
FibroScan (vibration-controlled transient elastography) has become the workhorse for non-invasive liver assessment in many clinics. The device sits against your skin between the ribs and sends a painless vibration pulse into the liver, measuring two things at once: liver stiffness (a proxy for fibrosis, reported in kilopascals) and the controlled attenuation parameter, or CAP score (a measure of fat content, reported in dB/m).
For detecting fat, the CAP score performs well at higher grades of steatosis. One study found it correctly identified about 90% of patients with severe steatosis. However, it also flagged about 81% of patients with only mild-to-moderate steatosis as having severe fat accumulation, meaning it tends to overestimate how much fat is present.11PubMed Central. The accuracy of FibroScan, FIB-4, and nonalcoholic fatty liver disease fibrosis score in predicting biopsy-defined fibrosis and steatosis across all fibrosis stages in patients with metabolic dysfunction associated steatotic liver disease Other research has found that CAP scores generally distinguish between grades of steatosis with good-to-excellent accuracy, with cutoffs around 263 dB/m for mild fat, 288 dB/m for moderate, and 330 dB/m for severe.12PubMed Central. The Accuracy of Ultrasound Controlled Attenuation Parameter in Diagnosing Hepatic Fat Content A separate study in Chinese patients confirmed strong overall accuracy, though it flagged that the measurement becomes less reliable as body mass index increases.13PubMed Central. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients
For detecting fibrosis, FibroScan’s liver stiffness measurement is useful but not perfect. That same study found it correctly identified fewer than half of patients with biopsy-confirmed advanced fibrosis, placing the rest into a lower-risk category.11PubMed Central. The accuracy of FibroScan, FIB-4, and nonalcoholic fatty liver disease fibrosis score in predicting biopsy-defined fibrosis and steatosis across all fibrosis stages in patients with metabolic dysfunction associated steatotic liver disease Obesity makes the reading less reliable because the vibration pulse has to travel through more tissue. If you have a high BMI, your doctor may use an XL probe designed for larger body types, though even then the results should be interpreted cautiously.
MRI-Based Techniques for Precision
When the question demands a precise answer, MRI is the gold standard among non-invasive tests. Two MRI-based techniques are especially relevant for fatty liver.
MRI-PDFF (proton density fat fraction) directly quantifies the percentage of fat in the liver. A systematic review of 22 studies covering nearly 2,900 patients found it distinguished any steatosis from no steatosis with an area under the curve of 0.97, which is about as close to perfect as non-invasive diagnostics get.14PubMed. Evaluation of MRI proton density fat fraction in hepatic steatosis: a systematic review and meta-analysis A fat fraction above roughly 5.7% is the emerging threshold for diagnosing steatosis. Chemical shift-encoded MRI, the technique behind MRI-PDFF, is now widely regarded as the most accurate and precise method available for measuring liver fat.15PubMed Central. Quantification of Liver Fat Content with CT and MRI: State of the Art It is also increasingly used in clinical drug trials as the primary way to track whether treatments reduce liver fat.16PubMed Central. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials
MRI elastography (MRE), the second technique, measures liver stiffness to assess fibrosis. A pooled analysis found MRE’s accuracy for detecting advanced fibrosis and cirrhosis was excellent, with area-under-the-curve values above 0.90, and its performance held up regardless of the patient’s BMI or degree of liver inflammation.17PubMed Central. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis A separate meta-analysis confirmed these findings, reporting that liver stiffness cutoffs of about 4.1 kPa for advanced fibrosis and 4.7 kPa for cirrhosis offered the best diagnostic balance.18Clinical Gastroenterology and Hepatology. Diagnostic Performance of Magnetic Resonance Elastography in Staging Liver Fibrosis: A Systematic Review and Meta-analysis of Individual Participant Data An AASLD-supported systematic review concluded that while transient elastography (FibroScan) has the largest body of evidence, MRE appears to be the most accurate non-invasive method for staging liver fibrosis overall.19PubMed. Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline
The reason MRI has not replaced everything else is practical: it is expensive, not available in every clinic, and requires 20 to 45 minutes in the scanner. FibroScan takes about ten minutes in a regular office visit. For most people, FibroScan or ultrasound combined with blood-based scores provides enough information to guide the next steps. MRI is reserved for situations where the results from simpler tools are ambiguous or where precise fat quantification matters.
When Liver Biopsy Is Still Considered
Liver biopsy remains the technical gold standard for diagnosing the more aggressive form of fatty liver disease, steatohepatitis, and for grading the exact stage of fibrosis. A small needle removes a thin cylinder of liver tissue, which a pathologist examines under a microscope. It is the only test that can directly confirm whether active inflammation and ballooning of liver cells are present, features that distinguish steatohepatitis from simple steatosis.20PubMed Central. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
That said, biopsy has real limitations. The sample represents less than 1/50,000th of the liver, so there is inherent sampling error: two biopsies from the same liver can come back with different grades. It also carries a small risk of complications including pain and bleeding, and it costs more than non-invasive alternatives. For these reasons, biopsy is typically reserved for cases where the diagnosis is uncertain, where other liver diseases need to be ruled out, or where knowing the exact degree of inflammation changes the treatment plan. Most people being evaluated for fatty liver will never need one.
Fatty Liver in People Who Are Not Overweight
One of the most common misconceptions about fatty liver is that it only affects people who are overweight or obese. In reality, a meaningful minority of people with fatty liver have a normal BMI, a condition sometimes called “lean NAFLD” or “lean MASLD.” Genetics play a significant role here. Variants in the PNPLA3 gene are more common among lean individuals with fatty liver than among their overweight counterparts, and these genetic variants roughly triple the risk of developing liver steatosis even after adjusting for BMI and metabolic syndrome.21Annals of Hepatology. PNPLA3 and SAMM50 variants are associated with lean nonalcoholic fatty liver disease in Asian population 22PubMed. Impact of PNPLA3 in Lean Individuals and in Cryptogenic Steatotic Liver Disease
Even in lean individuals with these genetic risk variants, cardiometabolic factors like insulin resistance, abnormal cholesterol, or elevated blood pressure usually still play a role. The genetics seem to lower the threshold at which these metabolic insults start depositing fat in the liver. If you are thin but have a family history of fatty liver, prediabetes, or abnormal lipids, the diagnosis should not be dismissed just because your weight looks fine.
Screening If You Have Diabetes or Prediabetes
If you have type 2 diabetes, the question is less “might I have fatty liver” and more “how advanced is it.” Fatty liver is extraordinarily common in this population, which is why clinical guidelines now recommend screening for it, and specifically for advanced fibrosis, in people with type 2 diabetes.23PubMed Central. Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment The American Diabetes Association’s 2024 guidelines included recommendations for screening and evaluating both fatty liver and liver fibrosis in people with type 2 diabetes and prediabetes.24PubMed Central. Interpretation of the 2024 American Diabetes Association guidelines for the comprehensive management of non-alcoholic fatty liver disease combined with diabetes mellitus
The typical approach uses a tiered strategy: calculate FIB-4 from routine lab work, and if the score falls in the intermediate or high-risk range, follow up with FibroScan or another elastography-based test. Across six major international guideline pathways for people with type 2 diabetes, the percentage ultimately referred to a liver specialist ended up at about 12%, and the accuracy of the various pathways was broadly similar, correctly classifying roughly three-quarters of patients.25Clinical Gastroenterology and Hepatology. Effectiveness of Six International Guidelines Using Fibrosis-4 and FibroScan for Risk Stratification of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes If you have diabetes and your doctor has never mentioned liver screening, it is reasonable to ask about it.
The Name Change You Might Encounter
You may see the terms NAFLD, MAFLD, and MASLD used interchangeably, which can be confusing. For decades, the standard label was “non-alcoholic fatty liver disease” (NAFLD), defined mainly by what it was not: fatty liver that was not caused by alcohol. More recently, expert groups have proposed renaming and reclassifying the condition to focus on what it is. MAFLD (metabolic dysfunction-associated fatty liver disease) requires evidence of metabolic dysfunction alongside liver fat. MASLD (metabolic associated steatotic liver disease) is the newest term, adopted by a broad international consensus, and it similarly ties the diagnosis to metabolic risk factors.26PubMed Central. Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort 27PubMed. Comparing NAFLD, MAFLD, and MASLD criteria for identifying significant liver fibrosis: A cross-sectional study
For you as a patient, the practical difference is small right now. The tests are the same, and the treatments are the same. But if you see “MASLD” on a radiology report or in a doctor’s note and do not recognize it, that is what it means: the updated name for the same condition.
Conditions That Can Look Like Fatty Liver
Not every case of fat in the liver is driven by metabolic syndrome. A number of other conditions can cause steatohepatitis that mimics the more common metabolic version, and missing them changes the treatment plan entirely. Expert guidance suggests ruling out secondary causes in all patients, with particular attention to a handful of conditions.28Journal of Hepatology. Diagnosis and management of secondary causes of steatohepatitis Celiac disease deserves consideration in people who are lean and have unexplained liver enzyme elevations, especially if there is any history of digestive symptoms or anemia. Wilson disease, a rare inherited condition of copper metabolism, should be investigated when fatty liver appears in a young person without typical metabolic risk factors. Certain medications, including some antidepressants, corticosteroids, tamoxifen, and antiretroviral drugs, can also cause hepatic fat accumulation that resolves once the medication is changed.
If your doctor suspects fatty liver but your metabolic profile is not particularly abnormal, or if your liver enzymes are elevated beyond what the degree of fat would explain, pushing for a broader workup is a good idea.
Breath Tests and Experimental Diagnostics
One area of active research is whether analyzing compounds in exhaled breath can help identify steatohepatitis without imaging or biopsy. In one study, researchers found that just three volatile organic compounds in a person’s breath could distinguish patients with steatohepatitis from those without it, with negative and positive predictive values around 82% and 81%, respectively. For context, elevated ALT levels alone had a negative predictive value of only 43% for the same distinction. The breath test was estimated to reduce the percentage of undiagnosed steatohepatitis patients from as high as 79% down to about 10%.29Journal of Hepatology. Non-invasive assessment of non-alcoholic steatohepatitis by analysis of volatile organic compounds in exhaled breath
This technology is not clinically available yet, and it needs validation in larger, more diverse populations before it could replace or supplement current screening tools. But it illustrates a broader trend: the diagnostic landscape for fatty liver is expanding beyond liver enzymes and ultrasound. Artificial intelligence tools trained on routine medical data and wearable devices capable of tracking metabolic markers are also being explored for risk stratification and self-management of the condition.30PubMed Central. Applications of Artificial Intelligence and Smart Devices in Metabolic Dysfunction-associated Steatotic Liver Disease Whether any of these emerge as practical screening tools in the next few years remains to be seen, but the trajectory is clearly toward earlier, cheaper, and less invasive detection.